Tel: 1-631-626-9181 (USA)   44-208-144-6005 (Europe)


Our promise to you:
Guaranteed product quality, expert customer support.


HBV Genome AAV Particles

Hepatitis B virus (HBV) infection is a major public health challenge. Current standard Chronic hepatitis B (CHB) treatments, including interferon-α and antiviral nucleos(t)ides are used to inhibit virus replication but cannot eliminate HBV or induce a protective immune response. Thus, there is a need to develop novel CHB therapeutic reagents.

Mouse models has been widely used to study immune tolerance to HBV antigens and to investigate the mechanisms of viral clearance. AAV vectors have advantages for efficient and long-term gene expression in basic research as well as clinical gene therapies. Among different serotypes of AAV, serotype 8 (AAV8) is the strongest hepatotropic type and is often used in liver related research. So far, several studies have successfully developed mouse models of long-term HBV infection by using AAV8 to deliver HBV genome DNA into mouse liver cells.

The AAV platform at Creative Biogene, which is led by a group of experienced scientists with in-depth knowledge in AAV production, is providing AAV particles containing HBV genome DNA for the discovery of novel targets and approaches for treatment of chronic HBV infection. The AAV-HBV particles provided by Creative Biogene allow long-term transduction, fast HBV modeling, and stable expression of hepatitis B antigen.

Browse All HBV Genome AAV Particles

For research use only. Not intended for any clinical use.